Skip to main content

Breast Cancer Research

Ausgabe Sonderheft 1/2000

Second International Symposium on the Molecular Biology of Breast Cancer

Inhalt (102 Artikel)

Meeting abstract

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2

SM Johnson, JA Shaw, RA Walker

Meeting abstract

BRCA1mutation analysis in breast and ovarian cancer families from Greece

I Konstantopoulou, C Croupis, A Ladopoulou, A Pantazidis, E Lianidou, K Venetsanou, E Efstathiou, M Petersen, J Janinis, G Fountzilas, E Chiotellis, D Yannoukakos

Meeting abstract

Germline TP53mutations in Finnish breast cancer patients

K Rapakko, M Allinen, K Syrjäkoski, P Vahteristo, P Huusko, K Vähäkangas, H Eerola, T Kainu, O-P Kallioniemi, H Nevanlinna, R Winqvist

Meeting abstract

Germline BRCA2 and somatic P53alterations in male breast cancer

B Csokay, N Udvarhelyi, E Olah

Meeting abstract

Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families

M Schwab, L Savelyeva, A Claas, H An, S Brouwers

Meeting abstract

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations

C Ghimenti, E Sensi, D Iandolo, G Cipollini, S Ricci, PF Conte, G Bevilacqua, MA Caligo

Meeting abstract

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer

O Stal, L Akerberg, B Nordenskjold, B Olsson, LE Rutqvist, L Skoog

Meeting abstract

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

J Alsner, M Yilmaz, P Guldberg, LL Hansen, J Overgaard

Meeting abstract

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients

A Langerød, TI Andersen, I Bukholm, A-L Børresen Dale

Meeting abstract

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers

E Sensi, C Ghimenti, G Cipollini, D Iandolo, G Naccarato, P Viacava, G Bevilacqua, MA Caligo

Meeting abstract

Constitutional alterations of the ATM gene in early-onset sporadic breast cancer

P Maillet, H Bonnefoi, A-P Sappino

Meeting abstract

Modulation of ATM gene expression in a murine mammary epithelial cell line

GV Vutskits, P Salmon, JV Soriano, C Cudre-Mauroux, D Trono, R Montesano, A-P Sappino

Meeting abstract

Loss of heterozygosity on chromosome arm 16q in breast cancer: clinical, molecular and statistical approaches

A-M Cleton-Jansen, HM van Beerendonk, NT ter Haar, PHC Eilers, HC van Houwelingen, BA Bonsing, VTHBM Smit, G-JB van Ommen, CJ Cornelisse

Meeting abstract

Analysis of chromosome alterations and the E-cadherin and FHIT genes in lobular breast cancer

S Ingvarsson, C Huiping, JG Jonasson, BA Agnarsson

Meeting abstract

Excluding TTC4 as a target for loss on chromosome 1p31 in human breast cancer

Y Hey, W Brintnell, L James, J Varley

Meeting abstract

Expression of variant forms of the MUC1 gene correlates with the invasiveness of breast cancer cells

R Zeillinger, B Schmid, D Tong, B Fasching, I Schiebl, M Stimpfl, A Obermair, S Leodolter

Meeting abstract

Estrogen-dependent c-jun upregulation may control cyclin D1 expression

MD Planas-Silva, J Liu Donaher, RA Weinberg

Meeting abstract

Development of a high throughput, molecular diagnostic assay for predicting telomerase activity in breast cancer cell lines and tissues

L Elmore, A Akalin, L Gollahon, G Clarke, M Grimes, RT Burks, A Ferreira-Gonzalez, C Garrett, S Holt

Meeting abstract

Genetic alterations in ductal carcinoma in situ and invasive carcinoma of the breast

E Robanus-Maandag, C Bosch, C Vos, H Peterse, M van de Vijver

Meeting abstract

Expression profiling of BRCA1 associated breast tumors

EMJJ Berns, IL van Staveren, L Verhoog, JA Foekens, JGM Klijn

Oral presentation

The pathology of inherited breast tumours

M Stratton

Oral presentation

The role of coactivators in oestrogen action

M Brown, JF de Mora

Oral presentation

Drug discovery in the p53 pathway

DP Lane, C Midgley, A Sparks, C Blattner, C Binden, S Laine

Oral presentation

Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium

AF Olumi, GD Grossfeld, SW Hayward, PR Carroll, GR Cunha, P Hein, TD Tlsty

Oral presentation

p53-mediated apoptosis and genomic instability syndromes

EA Spillare, XW Wang, SP Linke, A Robles, CC Harris

Oral presentation

p53 action in apoptosis and senescence

SW Lowe, CA Schmitt, G Ferbeyre, AW Lin, E de Stanchina, M Soengas

Meeting abstract

Clinical and pathological characteristics in patients with BRCA1/2-mutation associated with breast cancer (BC) with a long clinical follow-up

O Díez, C Pericay, M Domènech, J Brunet, J Cortés, J Balmaña, A Gómez, JJ López, MC Alonso, M Baiget

Meeting abstract

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial

Z Kote-Jarai, TP Powles, S Ashley, DF Easton, L Assersohn, N Sodha, M Dowsett, B Gusterson, A Tidy, G Mitchell, RA Eeles

Meeting abstract

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer

JI Martínez-Ferrandis, A Vega, P Marín-Garcia, F Barros, FJ Chaves, A Carracedo, ME Armengod, I Chirivella, A Lluch, J García-Conde, A Cervantes

Meeting abstract

One test to identify 50% of all Norwegian BRCA1 mutations

P Møller, E Hovig, K Lycke, RAP Stacy, OJ Dahlberg, A Hagen, B Hagen, K Løvslett, H Qvist, K Heimdal

Meeting abstract

X chromosome inactivation pattern in female patients with breast cancer

M Kristiansen, A Langer, GP Knudsen, BL Weber, A-L Børresen-Dale, KH Ørstavik

Meeting abstract

HRAS1 minisatellite alleles and breast cancer in Spanish women under age forty years

A Vega, JI Martínez, F Barros, P Marín-García, FJ Chavez, C Ruiz-Ponte, I Chirivella, A Lluch, A Cervantes, I García-Conde, ME Armengod, A Carracedo

Meeting abstract

Mammary-specific targeting of the murine BRCA2 breast cancer susceptibility gene in mice

NK Collins, KA McAllister, LM Bennett, K-U Wagner, T Ward, J Malphurs, G Goulding, EM Eddy, BJ Davis, RW Wiseman

Meeting abstract

Genetic variants of CYP19 (aromatase) and breast cancer risk

V Nedelcheva Kristensen, N Harada, N Yoshimura, E Haraldsen, PE Lønning, B Erikstein, R Kåresen, T Kristensen, A-L Børresen-Dale

Meeting abstract

Factors modulating integrin Beta I expression on the breast cancer cell lines MCF-7 and MDA-MB-231

CJ Pogson, CMW Chan, L-A Martin, GPH Gui, M Dowsett

Meeting abstract

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

TI Andersen, E Skovlund, IK Bukholm, U Jacobsen, R Kåresen, B Erikstein, J Nesland, A-L Børresen-Dale

Meeting abstract

BRCA2 interacting proteins

H Vidarsson, E Mikaelsdottir, JE Eyfjörd, H Ögmundsdóttir, T Rafnar, S Valgeirsdóttir

Meeting abstract

Embryonic lethality in the Brca1-1700T mouse model suggests inhibition of p53-dependent pathways

P Hohenstein, M Kielman, C Breukel, P Krimpenfort, A Berns, M Bennett, R Wiseman, C Cornelisse, G-J van Ommen, P Devilee, R Fodde

Meeting abstract

The GSTT1 genotype is associated with p53 mutation status of breast cancer tumours

K Gudmundsdóttir, L Tryggvadóttir, JE Eyfjörd

Meeting abstract

Screening breast cancer patients for Norwegian ATM mutations

K Laake, P Vu, TI Andersen, B Erikstein, R Kåresen, PE Lønning, E Skovlund, A-L Børresen-Dale

Meeting abstract

Analysis of Fhit expression in stages of breast cancer progression

M Campiglio, G Somenzi, P Aiello, F Wärnberg, L Holmberg, CM Croce, S Menard

Meeting abstract

A detailed physical map of a region within human chromosome 16q22.1

E Frengen, P Rocca-Serra, S Shaposhnikov, L Taine, J Thorsen, C Bépoldin, M Longy, H Prydz, F Dorion-Bonnet

Meeting abstract

p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy

S Geisler, B Smith-Sørensen, D Betticher, IK Bukholm, LA Akslen, A Kappeler, M Gugger, PE Lønning, A-L Børresen-Dale

Meeting abstract

Negative regulation of p53 expression is an essential, rate-limiting function of Jun in the control of cell cycle progression

M Schreiber, F Piu, A Kolbus, A Szabowski, U Möhle-Steinlein, J Tian, M Karin, P Angel, EF Wagner

Meeting abstract

Setting up an efficient and reliable screening method for novel c-Jun N-terminal kinase substrates

T Kallunki, C Holmberg, M Lerdrup-Hansen, T Herdegen, A Aronheim, M Jäättelä

Meeting abstract

Does a polymorphism in the CYP17 gene predict mammographic density?

G Ursin, SA Ingles, H Spencer Feigelson, GA Coetzee, L Bernstein, MC Pike, A Buley

Meeting abstract

Cytokeratin and mammaglobin as tumor markers in patients with high risk breast cancer

PF Ferrucci, C Rabascio, C Corsini, F Tealdo, M Paolucci, F Bertolini, H El Taani, G Martinelli

Meeting abstract

Promising method for DNA extraction from paraffin embedded archive material

A Bregård, P Vu, G Geitvik, A-L Børresen-Dale

Meeting abstract

REAL Real-Time!

F Boeckman, L Tan, K Hamby

Meeting abstract

Exact quantification of gene amplification in archival tissue sections by laser-assisted microdissection and real-time PCR

U Lehmann, S Glöckner, W Kleeberger, R von Wasielewski, H Kreipe

Meeting abstract

Screening for BRCA1 gene mutations by capillary electrophoretic REF-SSCP

P Kringen, HG Eiken, JC Pedersen, S Egedal, K Berg, KM Tveit, TI Andersen

Meeting abstract

Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite repeat

V Nedelcheva Kristensen, T Kristensen, A-L Børresen-Dale

Meeting abstract

Comparative genomic hybridisation analysis of myoepithelial carcinoma of the breast

C Jones, MP Foschini, R Chaggar, Y-J Lu, D Wells, JM Shipley, V Eusebi, SR Lakhani

Meeting abstract

Transcript profiles and genotyping of cancer tissue

C Malmqvist, M Sievertzon, A Gustafsson, A Holmberg, M Larsson, A Alderborn, M Uhlén, J Lundeberg

Meeting abstract

Relation of gene expression-based tumor subclasses to clinical phenotypes

T Sørlie, CM Perou, PE Lønning, PO Brown, D Botstein, A-L Børresen-Dale

Oral presentation

Molecular characteristics of inherited breast tumors

Å Borg, IA Hedenfalk, J Vallon-Christersson, N Loman, O Johannsson, H Olsson, DJ Duggan, Y Chen, M Bittner, O-P Kallioniemi, JM Trent

Oral presentation

Estrogen receptors α and β in the rodent mammary gland

S Saji, EV Jensen, S Nilsson, T Rylander, M Warner, J-Å Gustafsson

Oral presentation

Herceptin in clinical use - early 2000

CL Vogel

Oral presentation

Role of the ATM gene in radiation sensitivity, relevance to breast cancer treatment

J Hall, S Angèle, M Vuillaume, J-P Gérard, P Romestaing

Oral presentation

G1/S control and its deregulation in cancer

J Bartek, C Lukas, C Sørensen, E Santoni-Rugiu, J Bartkova, J Lukas

Oral presentation

Molecular control of apoptosis in the breast

C Streuli, A Gilmore, A Metcalfe, Y-J Lee, J Oliver, A Valentijn

Oral presentation

Blood assays for earlier detection of cancers

AB Pardee, RJ Guan, HL Ford, MV Fournier, K Martin, R Sager

Oral presentation

Predictive factors in breast cancer

J Klijn, E Berns, L Dorssers, J Foekens

Oral presentation

Tissue microarrays for high-throughput profiling in molecular oncology

O-P Kallioniemi, J Kononen, G Sauter

Oral presentation

Two molecular cytogenetic views of breast cancer

J Gray, K Chin, C Collins, P Yaswin, G Nonet, D Kowbel, W-L Kuo, E Garcia, C Ortiz de Solorzano, D Knowles, S Lockett, M Bissell, V Weaver, D Pinkel, D Albertson, A-L Børresen-Dale, F Waldnian

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.